From the Journals
From the Journals
Patients with stage 1 NSCLC more likely to die of other causes in short term
Patients with resected stage 1 non-small cell lung cancer are more likely to die of other causes in the short term.
From the Journals
Cost may hinder timely TKI initiation for CML
Nearly a third of Medicare beneficiaries with chronic myeloid leukemia did not initiate tyrosine kinase inhibitor therapy within 6 months of...
From the Journals
Calcium channel blocker reduces cardiac iron loading in thalassemia major
Amlodipine is a promising addition to chelation in patients with cardiac siderosis.
From the Journals
For HPV-negative women, longer screening intervals are effective
It may be safe to extend cervical cancer screening intervals beyond 5 years, at least for women who are not infected with human papillomavirus.
From the Journals
Rivaroxaban linked to more bleeding compared with dabigatran in elderly patients with nonvalvular AF
Rivaroxaban is associated with significantly more intra- and extracranial bleeding than is dabigatran in older patients who have nonvalvular...
From the Journals
Whole brain radiotherapy not beneficial for NSCLC metastasis
Whole brain radiotherapy provided no clinically significant benefit for most patients with metastatic non–small-cell lung cancer.
From the Journals
Pneumonitis with nivolumab treatment shows common radiographic patterns
Among 20 cancer patients treated with this PD-1 inhibitor who developed pneumonitis, cryptogenic organizing pneumonia was seen in 13.
From the Journals
IASLC lung cancer staging project proposes changes for new TNM classification
Key clinical point: New lung cancer classification to become effective January 2017. Major finding: Size will now be a descriptor in all T...
From the Journals
Wanted: Better evidence on fast-track lung resection
Key clinical point: Well-designed clinical trials are needed to determine the effectiveness of fast-track recovery pathways in lung resection.
From the Journals
NSQIP calculator shown inadequate to stratify risk in stage I non–small cell lung cancer.
Key clinical point: The current NSQIP Surgical Risk Calculator does not adequately estimate risk among patients with clinical stage I non–small...
From the Journals
Alectinib shows promise in crizotinib-refractory ALK-rearranged NSCLC
Key clinical point: Alectinib, an oral, small molecule inhibitor of ALK, showed promising clinical activity in crizotinib-refractory patients with...